Mayo Clinic Phage Program Biobank

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05314426

Enrollment

100

Registered

2022-04-06

Start date

2022-04-19

Completion date

2027-04-01

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteriophage Therapy

Brief summary

The purpose of this study is to help scientists and clinicians discover answers to research questions related to antibiotic-resistant bacterial infections, and the role that phage therapy plays as a possible treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ≥ 18 years of age. * Able to provide informed consent. * Individual must have a future treatment plan to receive or has historically received phage therapy.

Exclusion criteria

* Individuals , 18 years of age. * Unwilling/unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Enrollment of study participants	5 years	To recruit and enroll participants up to 100 participants who have received or will receive phage therapy treatment
Collection of biospecimens	5 years	Total number of biospecimens collected which may include blood samples and synovial fluid
Medical record review	5 years	Review the medical record of enrolled participants to ascertain any new health outcomes.
Increase treatment options and level of care for patients with bacterial infections	5 years	Total number of collaborations with clinical investigators and researchers at both Mayo Clinic and across the globe.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGina Suh, MD

Mayo Clinic

Outcome results